A5034715781- Testicular diseases and treatments
- Sarcoma Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Neuroblastoma Research and Treatments
- Bladder and Urothelial Cancer Treatments
- Epigenetics and DNA Methylation
- PARP inhibition in cancer therapy
- Urinary and Genital Oncology Studies
- Cancer Immunotherapy and Biomarkers
- Multiple Myeloma Research and Treatments
- Sexual Differentiation and Disorders
- Radiopharmaceutical Chemistry and Applications
- Cancer Treatment and Pharmacology
- Ovarian cancer diagnosis and treatment
- Urologic and reproductive health conditions
- Fibroblast Growth Factor Research
- Glioma Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Cancer, Lipids, and Metabolism
- Cancer therapeutics and mechanisms
- Metastasis and carcinoma case studies
- Nausea and vomiting management
- Chemotherapy-related skin toxicity
- Cancer Diagnosis and Treatment
- Chemotherapy-induced organ toxicity mitigation
Horizon Oncology Center
2023-2024
Indiana University School of Medicine
2012-2022
Indiana University – Purdue University Indianapolis
2013-2022
Indiana University Health
2013-2022
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
2016-2021
Indiana University
2015-2021
University School
2015-2021
Indiana Cancer Consortium
2021
Indianapolis Zoo
2016-2019
Indiana University Indianapolis
2018
Purpose To determine whether cotargeting poly (ADP-ribose) polymerase-1 plus androgen receptor is superior to inhibition in metastatic castration-resistant prostate cancer (mCRPC) and ETS fusions predict response. Patients Methods underwent site biopsy were stratified by status randomly assigned abiraterone prednisone without (arm A) or with veliparib B). Primary objectives were: confirmed prostate-specific antigen (PSA) response rate (RR) predicted Secondary safety, measurable disease RR...
The classification of the International Germ Cell Cancer Collaborative Group (IGCCCG) plays a pivotal role in management metastatic germ cell tumors but relies on data patients treated between 1975 and 1990.Data 9,728 men with nonseminomatous cisplatin- etoposide-based first-line chemotherapy 1990 2013 were collected from 30 institutions or collaborative groups Europe, North America, Australia. Clinical trial registry included. Primary end points progression-free survival (PFS) overall (OS)....
The classification of the International Germ-Cell Cancer Collaborative Group (IGCCCG) has been a major advance in management germ-cell tumors, but relies on data only 660 patients with seminoma treated between 1975 and 1990. We re-evaluated this database from large international consortium.Data 2,451 men metastatic cisplatin- etoposide-based first-line chemotherapy 1990 2013 were collected 30 institutions or collaborative groups Australia, Europe, North America. Clinical trial registry...
Purpose Patients with relapsed metastatic germ cell tumor (GCT) can be cured second-line and even third-line regimens. We report survival outcomes of patients treated high-dose chemotherapy (HDCT) peripheral-blood stem-cell transplantation (PBSCT) at Indiana University between 2004 2014. Methods conducted a retrospective analysis 364 consecutive GCT who progressed after cisplatin-based combination were subsequently HDCT PBSCT. Three hundred forty-one received two courses consisting 700 mg/m...
Aprepitant, a 5-HT3 receptor antagonist (5HT3-RA), and dexamethasone are standard antiemetic therapy for prevention of single-day, cisplatin-induced nausea vomiting. We conducted double-blind, placebo-controlled phase III cross-over study that compared aprepitant to placebo combined with prophylaxis (a 5HT3-RA dexamethasone) in patients receiving 5 days cisplatin combination chemotherapy testicular cancer.Patients two consecutive identical courses 5-day cisplatin-based were randomly assigned...
Purpose To define characteristics, treatment response, and outcomes of men with brain metastases (BM) from germ cell tumors (GCT). Patients Methods Data 523 BM GCT were collected retrospectively 46 centers in 13 countries by using standardized questionnaires. Clinical features correlated overall survival (OS) as the primary end point. Results present at initial diagnosis 228 (group A) relapse 295 B). OS 3 years (3-year OS) was superior group A versus B (48% v 27%; P < .001). Multiple...
We assessed prognostic factors, treatments and outcomes in patients with teratoma malignant transformation, a rare occurrence among germ cell tumors.Data on diagnosed transformation between June 1981 August 2014 were collected across 5 referral centers. Chemotherapy was dichotomized as based tumor or transformation. Cox analyses done to evaluate factors of overall survival, the primary end point. Each factor evaluated univariable model. Forward stepwise selection used construct an optimal...
Purpose The TAXYNERGY trial ( ClinicalTrials.gov identifier: NCT01718353) evaluated clinical benefit from early taxane switch and circulating tumor cell (CTC) biomarkers to interrogate mechanisms of sensitivity or resistance taxanes in men with chemotherapy-naïve, metastatic, castration-resistant prostate cancer. Patients Methods were randomly assigned 2:1 docetaxel cabazitaxel. Men who did not achieve ≥ 30% prostate-specific antigen (PSA) decline by cycle 4 (C4) switched taxane. primary...
BackgroundTo report our experience utilizing a multidisciplinary clinic (MDC) at Indiana University (IU) since the publication of International Germ Cell Cancer Collaborative Group (IGCCCG), and to compare overall survival (OS) that National Institute (NCI) Surveillance, Epidemiology, End Results (SEER) Program.Patients methodsWe conducted retrospective analysis all patients with metastatic germ-cell tumor (GCT) seen IU from 1998 2014. A total 1611 consecutive were identified, whom 704...
Nausea and vomiting, unrelated to chemotherapy, can be substantial symptoms in patients with advanced cancer. To evaluate the utility of olanzapine for treating chronic nausea/vomiting, This study is a double-line, placebo-controlled, randomized clinical trial conducted from July 2017 through April 2019, analysis 2019. Eligible participants were outpatients cancer who had persistent nausea/vomiting without having chemotherapy or radiotherapy prior 14 days. Chronic nausea was present at least...
// Costantine Albany 1 , Mary P. Hever-Jardine 2 Katherine M. von Herrmann Christina Y. Yim Janice Tam Joshua Warzecha Leah Shin Sarah E. Bock Brian S. Curran Aneeq Chaudhry Fred Kim George Sandusky 5 Pietro Taverna 3 J. Freemantle 4 Brock C. Christensen 6 Lawrence H. Einhorn Michael Spinella Division of Hematology/Oncology, Melvin and Bren Simon Cancer Center, Indiana University School Medicine, Indianapolis, IN, USA Departments Pharmacology Toxicology Epidemiology, Geisel Medicine at...
Abstract Purpose: To assess the clinical and pharmacodynamic activity of dovitinib in a treatment-resistant, molecularly enriched non–muscle-invasive urothelial carcinoma bladder (NMIUC) population. Experimental Design: A multi-site pilot phase II trial was conducted. Key eligibility criteria included following: Bacillus Calmette-Guerin (BCG)-unresponsive NMIUC (&gt;2 prior intravesical regimens) with increased phosphorylated FGFR3 (pFGFR3) expression by centrally analyzed...
Abstract Purpose: To report efficacy and safety of samotolisib (LY3023414; PI3K/mTOR dual kinase DNA-dependent protein inhibitor) plus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) following progression on abiraterone. Patients Methods: In this double-blind, placebo-controlled phase Ib/II study (NCT02407054), a lead-in segment for evaluating pharmacokinetics combination, advanced prior abiraterone were randomized to receive (160 mg daily)/samotolisib...
PURPOSE Two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and rucaparib) are US Food Drug Administration–approved for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/ 2 mutations, but the relative efficacy of PARP inhibition in BRCA1- versus BRCA2-altered mCRPC is understudied. METHODS We conducted a multicenter retrospective analysis involving 12 sites. collected genomic clinical data from 123 2-altered who were treated inhibitors. The...
Prostate cancer (PC) is the most commonly diagnosed nonskin malignancy and second common cause of death among men in United States. Epigenetics study heritable changes gene expression caused by mechanisms other than underlying DNA sequences. Two epigenetic mechanisms, methylation histone modification, have demonstrated critical roles prostate growth metastasis. hypermethylation cytosine-guanine (CpG) rich sequence islands within promoter regions widespread during neoplastic transformation...
BACKGROUND We sought to identify potential clinical variables associated with outcomes after radium‐223 therapy in routine practice. METHODS Consecutive non‐trial mCRPC patients who received ≥1 dose of radium dichloride‐223 at four academic and one community urology‐specific cancer centers from May 2013 June 2014 were retrospectively identified. Association baseline on‐therapy number doses including overall survival analyzed using chi‐square statistics, cox proportional hazards, Kaplan–Meier...
Abstract Background Cytotoxic therapy for relapsed and refractory germ cell tumors or metastatic sex cord stromal is rarely effective often accompanied by high adverse event rates. Expression of CD30 has been observed in testicular cancers, patients with CD30-expressing embryonal carcinomas have worse progression-free survival overall than those CD30-negative tumors. The objective this study (NCT01461538) was to characterize the antitumor activity brentuximab vedotin nonlymphomatous...